Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.8 SEK | -0.32% | +7.12% | +110.67% |
May. 08 | Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 65.65M 6.11M | Sales 2025 * | 138M 12.86M | Capitalization | 820M 76.31M |
---|---|---|---|---|---|
Net income 2024 * | -111M -10.34M | Net income 2025 * | -28M -2.61M | EV / Sales 2024 * | 12.3 x |
Net cash position 2024 * | 11.93M 1.11M | Net Debt 2025 * | 259M 24.11M | EV / Sales 2025 * | 7.81 x |
P/E ratio 2024 * |
-5.13
x | P/E ratio 2025 * |
-4.36
x | Employees | 34 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 57.48% |
Latest transcript on IRLAB Therapeutics AB
1 day | -0.32% | ||
1 week | +7.12% | ||
Current month | +38.60% | ||
1 month | +37.39% | ||
3 months | +10.10% | ||
6 months | +138.67% | ||
Current year | +110.67% |
Managers | Title | Age | Since |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 12-12-31 |
Chief Executive Officer | 71 | 17-05-05 | |
Nicholas Waters
FOU | Founder | 62 | 12-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 15-12-31 |
Rein Piir
BRD | Director/Board Member | 66 | 15-12-31 |
Chairman | 66 | 19-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 15.8 | -0.32% | 60,993 |
24-05-22 | 15.85 | +1.93% | 58,853 |
24-05-21 | 15.55 | -0.32% | 44,096 |
24-05-20 | 15.6 | +2.30% | 66,996 |
24-05-17 | 15.25 | +3.39% | 100,168 |
Delayed Quote Nasdaq Stockholm, May 23, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+110.67% | 76.32M | |
+38.69% | 728B | |
+34.28% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+17.02% | 244B | |
+9.31% | 207B | |
-5.07% | 205B | |
-0.35% | 163B |
- Stock Market
- Equities
- IRLAB A Stock